COPENHAGEN, Oct 8 (Reuters) – Tesaro’s experimental
drug niraparib improved outcomes for a broad range of women with
recurrent ovarian cancer in a clinical study, boosting prospects
for the product,…
The post Tesaro ovarian cancer drug shows broad benefits in study appeared first on NASDAQ.